Methods for inhibiting fibrosis in a subject in need thereof
In one aspect, the invention provides methods for treating, inhibiting, alleviating or preventing fibrosis in a mammalian subject suffering, or at risk of developing a disease or disorder caused or exacerbated by fibrosis and/or inflammation. In one embodiment, the invention provides methods of treating a subject suffering from renal fibrosis. In one embodiment, the invention provides methods of reducing proteinuria in a subject suffering from a renal disease or condition associated with proteinuria. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
1. A method of treating a human subject suffering from steroid-dependent Immunoglobulin A Nephropathy (IgAN) comprising:
(a) identifying a human subject having steroid-dependent IgAN, wherein the human subject having steroid-dependent IgAN has been maintained on a stable dose of corticosteroids for at least 12 weeks; and
(b) administering to the subject a composition comprising a MASP-2 inhibitory monoclonal antibody, or antigen-binding fragment thereof that specifically binds to human MASP-2, in an amount effective and for a time sufficient to achieve at least a 30% reduction in 24-hour urine protein excretion as compared to baseline 24-hour urine protein excretion in the subject prior to MASP-2 inhibitory antibody treatment.
2. The method of claim 1 , wherein the antibody or fragment thereof is selected from the group consisting of a recombinant antibody, an antibody having reduced effector function, a chimeric antibody, a humanized antibody, and a human antibody.
3. The method of claim 1 , wherein the MASP-2 inhibitory antibody does not substantially inhibit the classical pathway.
4. The method of claim 1 , wherein the MASP-2 inhibitory antibody inhibits C3b deposition in 90% human serum with an IC 50 of 30 nM or less.
5. The method of claim 1 , wherein the MASP-2 inhibitory antibody or antigen-binding fragment thereof is administered in an amount effective and for a time sufficient to achieve at least a 40% reduction in 24-hour urine protein excretion as compared to baseline 24-hour urine protein excretion in the subject prior to treatment.
6. The method of claim 1 , wherein the MASP-2 inhibitory antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising CDR-H1, CDR-H2 and CDR-H3 of the amino acid sequence set forth as SEQ ID NO:67 and a light chain variable region comprising CDR-L1, CDR-L2 and CDR-L3 of the amino acid sequence set forth as SEQ ID NO: 69.
7. The method of claim 1 , wherein the MASP-2 inhibitory antibody or antigen-binding fragment thereof comprises a heavy chain variable region set forth as SEQ ID NO:67 and a light chain variable region set forth as SEQ ID NO:69.
8. The method of claim 1 , wherein the MASP-2 inhibitory monoclonal antibody, or antigen-binding fragment thereof that specifically binds to human MASP-2, is administered in an amount effective and for a time sufficient to decrease the corticosteroid dosage in said subject as compared to the corticosteroid dosage required to maintain stable renal function in said subject prior to treatment with the composition.